-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On April 6, Jincheng Pharmaceutical issued two consecutive good news announcements, namely: Ceftezole Sodium for Injection, Cefmetazole Sodium for Injection, Cefdime for Injection of Jincheng Jinsu, a holding subsidiary of the company.
Obtained drug approval for 3 varieties of oxazine sodium; cefadroxil capsules of Jincheng Suzhi, a wholly-owned subsidiary of the company, have been reviewed
.
Three varieties have obtained drug approvals The three varieties that have obtained drug approvals are all anti-infective drugs
.
Among them, ceftizole sodium is the first-generation cephalosporin, which is mainly used clinically for pneumonia, bronchitis, bronchiectasis, sepsis, secondary infection of chronic respiratory diseases caused by sensitive bacteria, lung abscess, peritonitis, renal pelvis Anti-infective treatment for diseases such as nephritis, cystitis and urethritis
.
The original research company of ceftizole sodium for injection is Celoslin.
In China, in addition to Jincheng Jinsu, there are also many companies such as Lukang Pharmaceutical, Shanghai Pharmaceutical Xinya Pharmaceutical, Livzon Group and other companies that have production approvals
.
Cefmetazole sodium is a cephalosporin cephalosporin, used for respiratory system infections, biliary tract infections, urinary tract infections, obstetrics and gynecology bacterial infections, skin and soft tissue infections and post-operative infection prevention caused by sensitive bacteria
.
The original research company of cefmetazole sodium for injection is Cefmetazon
.
In China, in addition to Jincheng Jinsu, many companies such as Fukang Pharmaceutical and Qingyutang also have production approvals
.
In terms of consistency evaluation, there are currently 6 companies that have over-evaluated
.
According to data from Minet.
com, in 2020, the sales of cefmetazole sodium for injection in urban public and county-level public hospitals will be about 1.
4 billion yuan
.
Cefdizazine sodium is a third-generation cephalosporin, which is mainly used clinically for pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infection, and gonococcal urethritis caused by sensitive bacteria such as Streptococcus and pneumococcus.
, cholecystitis, cholangitis, gynecological infection, sepsis and otitis media, etc.
.
Cefdizazine Sodium for Injection was developed and marketed by Japan Dapeng Pharmaceutical Industry Co.
,
Ltd.
In addition to Jincheng Jinsu, domestic enterprises include Luoxin Pharmaceutical, Hebei Huamin Pharmaceutical, Dawnrays Pharmaceutical,
etc.
In terms of consistency evaluation, Chengdu Beite and Kelun Pharmaceuticals have been reviewed at present
.
According to the data of Minet.
com, cefodizime sodium for injection is a large variety with over 2 billion
.
The company believes that these three varieties have obtained drug approvals, which enriches the company's cephalosporin product pipeline and is conducive to further enhancing the market competitiveness of the company's cephalosporin series products
.
As the sales of medicines may be affected by comprehensive factors such as national policies and changes in the market environment, there are uncertainties
.
Investors are advised to pay attention to risks and invest rationally
.
1 Variety Review Cefadroxil is a first-generation oral cephalosporin.
The original research company is WARNER CHILCOTT.
This product was approved by the FDA in 1978.
It is suitable for urinary tract infections, skin and soft tissue infections, and acute tonsillitis caused by sensitive bacteria.
Acute pharyngitis, otitis media and lung infection
.
In China, in addition to Jincheng Suzhi, there are many companies that currently hold the approval for the production of cefadroxil capsules, such as Lukang Pharmaceutical and CSPC Zhongnuo Pharmaceutical (Shijiazhuang)
.
The company believes that after the variety has been evaluated, it will help to further improve the technical level of the product, improve the market competitiveness, and accumulate valuable experience for the follow-up product to carry out the consistency evaluation of generic drugs
.
As the sales of medicines may be affected by comprehensive factors such as national policies and changes in the market environment, there are uncertainties
.
Investors are advised to pay attention to risks and invest rationally
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Obtained drug approval for 3 varieties of oxazine sodium; cefadroxil capsules of Jincheng Suzhi, a wholly-owned subsidiary of the company, have been reviewed
.
Three varieties have obtained drug approvals The three varieties that have obtained drug approvals are all anti-infective drugs
.
Among them, ceftizole sodium is the first-generation cephalosporin, which is mainly used clinically for pneumonia, bronchitis, bronchiectasis, sepsis, secondary infection of chronic respiratory diseases caused by sensitive bacteria, lung abscess, peritonitis, renal pelvis Anti-infective treatment for diseases such as nephritis, cystitis and urethritis
.
The original research company of ceftizole sodium for injection is Celoslin.
In China, in addition to Jincheng Jinsu, there are also many companies such as Lukang Pharmaceutical, Shanghai Pharmaceutical Xinya Pharmaceutical, Livzon Group and other companies that have production approvals
.
Cefmetazole sodium is a cephalosporin cephalosporin, used for respiratory system infections, biliary tract infections, urinary tract infections, obstetrics and gynecology bacterial infections, skin and soft tissue infections and post-operative infection prevention caused by sensitive bacteria
.
The original research company of cefmetazole sodium for injection is Cefmetazon
.
In China, in addition to Jincheng Jinsu, many companies such as Fukang Pharmaceutical and Qingyutang also have production approvals
.
In terms of consistency evaluation, there are currently 6 companies that have over-evaluated
.
According to data from Minet.
com, in 2020, the sales of cefmetazole sodium for injection in urban public and county-level public hospitals will be about 1.
4 billion yuan
.
Cefdizazine sodium is a third-generation cephalosporin, which is mainly used clinically for pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infection, and gonococcal urethritis caused by sensitive bacteria such as Streptococcus and pneumococcus.
, cholecystitis, cholangitis, gynecological infection, sepsis and otitis media, etc.
.
Cefdizazine Sodium for Injection was developed and marketed by Japan Dapeng Pharmaceutical Industry Co.
,
Ltd.
In addition to Jincheng Jinsu, domestic enterprises include Luoxin Pharmaceutical, Hebei Huamin Pharmaceutical, Dawnrays Pharmaceutical,
etc.
In terms of consistency evaluation, Chengdu Beite and Kelun Pharmaceuticals have been reviewed at present
.
According to the data of Minet.
com, cefodizime sodium for injection is a large variety with over 2 billion
.
The company believes that these three varieties have obtained drug approvals, which enriches the company's cephalosporin product pipeline and is conducive to further enhancing the market competitiveness of the company's cephalosporin series products
.
As the sales of medicines may be affected by comprehensive factors such as national policies and changes in the market environment, there are uncertainties
.
Investors are advised to pay attention to risks and invest rationally
.
1 Variety Review Cefadroxil is a first-generation oral cephalosporin.
The original research company is WARNER CHILCOTT.
This product was approved by the FDA in 1978.
It is suitable for urinary tract infections, skin and soft tissue infections, and acute tonsillitis caused by sensitive bacteria.
Acute pharyngitis, otitis media and lung infection
.
In China, in addition to Jincheng Suzhi, there are many companies that currently hold the approval for the production of cefadroxil capsules, such as Lukang Pharmaceutical and CSPC Zhongnuo Pharmaceutical (Shijiazhuang)
.
The company believes that after the variety has been evaluated, it will help to further improve the technical level of the product, improve the market competitiveness, and accumulate valuable experience for the follow-up product to carry out the consistency evaluation of generic drugs
.
As the sales of medicines may be affected by comprehensive factors such as national policies and changes in the market environment, there are uncertainties
.
Investors are advised to pay attention to risks and invest rationally
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
